The treatment of ruptured hepatocellular carcinoma by emergent TAE in combination with sequential resection or intraperitoneal hyperthermic perfusion chemotherapy

Abstract

Abstract: Objective To investigate the clinical value of emergent transcatheter arterial embolization (TAE) in combination with sequential resection or conserved intraperitoneal hyperthermic perfusion chemotherapy for the treatment of ruptured hepatocellular carcinoma.Methods Thirty cases of ruptured hepatocellular carcinoma that were diagnosed and treated from January 2015 to June 2021 were retrospectively analyzed. The patients were divided into a surgical treatment group (10 cases) and a conservative treatment group (20 cases). The 1-, 2-, 3- and 5-year survival rates of the two groups were compared.Results The 1-year survival rate of the surgical treatment group was 70%, which was significantly higher than that of the conservative treatment group (35%). The 2-year, 3-year and 5-year survival rates of the surgical treatment group were 40%, 20% and 10%, which were 0% in the conservative treatment group. The long-term survival rate of the surgical group was significantly higher than that of the conservative treatment group.Conclusion For patients with ruptured hepatocellular carcinoma that have surgical indication, emergent TAE combined with sequential surgical resection followed by postoperative intraperitoneal hyperthermic perfusion chemotherapy and other combined treatments can achieve satisfactory prognosis.

Key words: hepatocellular carcinoma, ruptured, surgical resection, transcatheter arterial embolization, intraperitoneal hyperthermic perfusion chemotherapy, combined treatments

DUAN Chang-hu, LIU Xiao-chen, DUAN Jian-feng, DING Jian-long, ZHAO Li-fei, TAI Sheng. The treatment of ruptured hepatocellular carcinoma by emergent TAE in combination with sequential resection or intraperitoneal hyperthermic perfusion chemotherapy[J]. Chinese Hepatolgy, 2022, 27(4): 455-459.

References

[1] Sahu SK,Chawla YK,Dhiman RK,et al.Rupture of hepatocellular carcinoma: a review of literature.J Clin Exp Hepatol, 2019,9:245-256.
[2] 刘允怡.自发性肝细胞癌破裂的处理策略.中华消化外科杂志,2020,19:113-118.
[3] 尹兵,麻勇.肝癌破裂相关急腹症的诊治体会 .国际外科学杂志,2020,47:649-654.
[4] Demetrious M, Jeffery C, Steven HS, et al.Management, outcomes, and prognostic factors of ruptured hepatocellular carcinoma: A systematic review.J Surg Oncol,2018,117:341-353.
[5] 王新伟, 王维娜, 张宗利. 肝细胞癌自发性破裂出血行肝切除术的疗效及生存分析. 临床肝胆病杂志, 2019, 35: 114-118.
[6] Aoki T,Kokudo N,Matsuyama Y,et al.Prognostic impact of spontaneous tumor rupture in patients with hepatocellular carcinoma: an analysis of 1160 cases from a nationwide survey.Ann Surg, 2014,259:532-542.
[7] Yang T, Sun YF, Zhang J, et al. Partial hepatectomy for ruptured hepatocellular carcinoma. Br J Surg, 2013,100:1071-1079.
[8] Wu JJ, Zhu P, Zhang ZG, et al. Spontaneous rupture of hepatocellular carcinoma: Optimal timing of partial hepatectomy. Eur J Surg Oncol,2019,45:1887-1894.
[9] Zhou SJ,Zhang EL,Liang BY,et al.Distilled Water Lavage During Surgery Improves Long-Term Outcomes of Patients with Ruptured Hepatocellular Carcinoma.J Gastrointest Surg,2015 ,19: 1262-1270.
[10] 李大伟, 王亚丽, 房芹. TACE术联合¹²⁵I放射性粒子植入序贯治疗HCC的预后及其影响因素. 肝脏, 2019, 24: 1258-1260.
[11] 中国医师协会肝癌专业员会精确放疗学组, 中国研究型医院学会放射肿瘤学专业委员会肝癌学组, 中国研究型医院学会肿瘤放射生物与多模态诊疗专业委员会, 等. 原发性肝癌放射治疗专家共识(2020年版). 临床肝胆病杂志, 2021, 37: 296-301.

[1]	CHEN Ping, ZHOU He-ping, ZHU Ya-nan. A comparison between the diagnostic accuracies of ¹⁸F-FDG PET/CT for hepatocellular carcinoma and cholangiocarcinoma [J]. Chinese Hepatolgy, 2022, 27(4): 470-471.
[2]	LIU Xiao-bin, TANG Yu-fu, CHEN Ming-yang, XIN Jian, ZHANG Wei. The expression of ALDH1A1 and miR-140-5p in hepatocellular carcinoma and the relationship with chemotherapy sensitivity [J]. Chinese Hepatolgy, 2022, 27(4): 472-477.
[3]	DING Xiao-peng, TIE Jun, YU Jia-hao, REN Peng-wei, XUAN Guo-yun, MA Shuo-yi, GUO Chang-cun, HAN Ying, ZHOU Xin-min. Efficacy and safety of TACE combined with anti-angiogenic drugs and PD-1 inhibitors in the treatment of intermediate/advanced HCC [J]. Chinese Hepatolgy, 2022, 27(3): 277-280.
[4]	LI Long, ZHENG Zhen-dong, DU Cheng, LIU Bo-na. Efficacy of bevacizumab combined with TACE in the treatment of advanced hepatocellular carcinoma [J]. Chinese Hepatolgy, 2022, 27(3): 281-283.
[5]	CHANG Li-xian, LIU Chun-yun, XIE Pian. Relationship between Glypican-3 expression level and tumor biological behavior in hepatocellular carcinoma tissues [J]. Chinese Hepatolgy, 2022, 27(3): 284-287.
[6]	YANG Yi, XI Zi-han, ZHANG Lin-ying. The expression and clinical significance of AURKB and TP53 in hepatocellular carcinoma [J]. Chinese Hepatolgy, 2022, 27(2): 188-192.
[7]	FENG Quan-ye, GENG Cheng-jun, YIN Hui-kang. Application of T2WI sequence image TA in the differential diagnosis of nodules and small hepatocellular carcinoma under the background of liver cirrhosis [J]. Chinese Hepatolgy, 2022, 27(2): 193-195.
[8]	ZHANG Feng-xiao, BAI Xue-song, HU Jinghua. Prediction of post-hepatectomy liver failure for hepatocellular carcinoma by model for end-stage liver disease and standardized future liver remnant [J]. Chinese Hepatolgy, 2022, 27(2): 196-198.
[9]	HE Xiao-yan, ZHANG Qiang-nu, YANG Liu, WANG Gui-zhi. RNA-binding protein CSTF2 promotes the proliferation and migration of hepatocellular carcinoma cells by regulating MCM6 [J]. Chinese Hepatolgy, 2022, 27(2): 203-209.
[10]	JI Qin, SHEN Yu-chneg, SHAO Chun-yan. The value of PIVKA Ⅱ and serum AFP - L3 levels for evaluating the prognosis of primary liver cancer after TACE Therapy [J]. Chinese Hepatolgy, 2022, 27(2): 210-212.
[11]	WANG Jia-le, LI Cheng, LI Guang-ming. The mechanism of lncRNA TSIX inhibiting proliferation and invasion of hepatocellular carcinoma cell by targeting miR-548-a-3p [J]. Chinese Hepatolgy, 2022, 27(2): 213-217.
[12]	LI Jiao-jiao, SHI Dou-dou, HUANG Qi-chao, TAO Mei. Expression and clinical significance of ACSL1 in hepatocellular carcinoma [J]. Chinese Hepatolgy, 2022, 27(1): 81-85.
[13]	SUN Wen-wen, ZHANG Ling-yun. Expression and significance of folate metabolic pathway genes in hepatocellular carcinoma——A bioinformatics analysis [J]. Chinese Hepatolgy, 2021, 26(8): 851-856.
[14]	WANG Kai-le, JIN Xian-de, WANG Zhen, ZHANG Xin, ZHOU Jie. The value of multimodal imaging quantitative parameters in the differential diagnosis of small hepatocellular carcinoma and dysplastic nodules on the background of cirrhosis [J]. Chinese Hepatolgy, 2021, 26(8): 861-865.
[15]	LV Shao-dong, WEI Yong-peng, WANG Zhuo, YUAN Jian-yong, LU Jun-hua. MST1 and MST2 in Hippo signaling pathway were critical in stemness maintenance and self-renewal of hepatocellular carcinoma stem cells [J]. Chinese Hepatolgy, 2021, 26(8): 866-870.